Login to Your Account



Nucana set to follow 'groundbreaking' ASCO data with phase III trial

By Nuala Moran
Staff Writer

Friday, May 29, 2015
LONDON – Nucana Ltd. is poised to start phase III development of its lead product Acelarin after reporting what it claimed as "groundbreaking" phase I/II data for the modified version of gemcitabine at the American Society of Clinical Oncology meeting in Chicago on Saturday.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription